dc.contributor.author | İrfan Cicin | |
dc.contributor.author | Tahsin Özatlı | |
dc.contributor.author | Esma Türkmen | |
dc.contributor.author | Türkan Özturk | |
dc.contributor.author | Melike Özçelik | |
dc.contributor.author | Devrim Çabuk | |
dc.contributor.author | Ayşe Gökdurnalı | |
dc.contributor.author | Özlem Balvan | |
dc.contributor.author | Yaşar Yıldız | |
dc.contributor.author | Metin Şeker | |
dc.contributor.author | Nuriye Özdemir | |
dc.contributor.author | Burcu Yapar | |
dc.contributor.author | Özgür Tanrıverdi | |
dc.contributor.author | Yusuf Günaydin | |
dc.contributor.author | Serkan Menekşe | |
dc.contributor.author | Berna Öksüzoğlu | |
dc.contributor.author | Asude Aksoy | |
dc.contributor.author | Bülent Erdogan | |
dc.contributor.author | M Bekir Hacıoglu | |
dc.contributor.author | Erkan Arpaci | |
dc.contributor.author | Alper Sevinç | |
dc.date.accessioned | 23.07.201910:49:13 | |
dc.date.accessioned | 2019-07-23T16:41:48Z | |
dc.date.available | 23.07.201910:49:13 | |
dc.date.available | 2019-07-23T16:41:48Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 2146-3123 | |
dc.identifier.uri | http://www.trdizin.gov.tr/publication/paper/detail/TWpBME5UWXdNQT09 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/4231 | |
dc.description.abstract | Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarco-mas have not yet been clearly defined. Although car-cinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive fac-tors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcino-sarcomas may benefit more from adjuvant CT.Aims: We aimed to define the prognostic and predic-tive factors associated with treatment options in ovar-ian (OCS) and uterine carcinosarcoma (UCS).Study Design: Retrospective cross-sectional studyMethods: We retrospectively reviewed the medical re-cords of patients with ovarian and uterine carcinosar-coma from 2000 to 2013, and 127 women were includ-ed in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey be-tween 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data ob-tained from well-kept medical records were included in this study. Stage IV tumours were excluded. The pa-tient records were retrospectively reviewed. Data from 104 patients were evaluated for this study.Results: Age (>=70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dis-section did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adju-vant radiotherapy tended to increase the median OS | en_US |
dc.description.abstract | Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarco-mas have not yet been clearly defined. Although car-cinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive fac-tors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcino-sarcomas may benefit more from adjuvant CT.Aims: We aimed to define the prognostic and predic-tive factors associated with treatment options in ovar-ian (OCS) and uterine carcinosarcoma (UCS).Study Design: Retrospective cross-sectional studyMethods: We retrospectively reviewed the medical re-cords of patients with ovarian and uterine carcinosar-coma from 2000 to 2013, and 127 women were includ-ed in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey be-tween 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data ob-tained from well-kept medical records were included in this study. Stage IV tumours were excluded. The pa-tient records were retrospectively reviewed. Data from 104 patients were evaluated for this study.Results: Age (>=70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dis-section did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adju-vant radiotherapy tended to increase the median OS | en_US |
dc.language.iso | eng | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Cerrahi | en_US |
dc.title | Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas | en_US |
dc.type | article | en_US |
dc.relation.journal | Balkan Medical Journal | en_US |
dc.contributor.department | Sivas Cumhuriyet Üniversitesi | en_US |
dc.identifier.volume | 33 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.endpage | 524 | en_US |
dc.identifier.startpage | 517 | en_US |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US] |